Previous close | 41.80 |
Open | 42.17 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 42.17 - 42.58 |
52-week range | 36.88 - 99.88 |
Volume | |
Avg. volume | 28,545 |
Market cap | 12.428B |
Beta (5Y monthly) | 0.47 |
PE ratio (TTM) | 34.37 |
EPS (TTM) | 1.24 |
Earnings date | N/A |
Forward dividend & yield | 1.33 (3.50%) |
Ex-dividend date | 29 Mar 2022 |
1y target est | 45.00 |
APAM, CNVY, and ESALY have been added to the Zacks Rank #5 (Strong Sell) List on June 8, 2022.
GOGL, ESALY, and ADM made it to the Zacks Rank #1 (Strong Buy) income stocks list on March 1, 2022
The company's blockbuster cancer drug Keytruda was approved in Japan to treat patients with certain types of endometrial cancer.